Endocrine-disrupting chemicals are a significant concern to public health.
Differences in surgical management, in adjuvant therapy, and in patient populations seem to have no effect on the high 3-year survival and 3-year recurrence-free survival rates associated with preoperative grade 1 endometrial cancer.
Researchers from Duke University and Toronto Sunnybrook Regional Cancer Center performed a retrospective analysis involving 494 women from the two institutions identified with preoperative, central-review–confirming, grade 1, endometroid, endometrial cancer.
While the two groups of women were similar in grade, final histology, type of hysterectomy, and length of hospital stay, the women from Sunnybrook were a few years older (aged 62 years compared with 59 years at Duke), were more than twice as likely as the women at Duke to have capillary lymphatic space involvement (18.2% vs. 8.3%, respectively), were more than three times as likely as the women at Duke to have cervical involvement (12.2% vs. 3.7%, respectively), were less likely than the women at Duke to have been operated on by a gynecologic oncologist (66% vs. 91%, respectively), and were three times more likely than their counterparts to receive adjuvant radiation treatment (20.7% vs. 7%, respectively).
Bernardini MQ, May T, Khalifa MA, et al. Evaluation of two management strategies for preoperative grade 1 endometrial cancer. Obstet Gynecol. 2009;114:7-15.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More